Compliance With Antibiotic Treatment in General Practice

NCT ID: NCT01291251

Last Updated: 2012-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

270 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The guidelines of The Norwegian authorities concerning the use of antibiotics in general practice state that for several common diseases such as pneumonia and tonsillitis, antibiotics should be given four times daily instead of three times daily. The study´s aim is to see whether the patient compliance is significantly reduced in antibiotic regimes of 3 or 4 daily doses as compared to 1 or 2 daily doses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients given antibiotic tablets, independent of diagnosis and medicament, are included. All patients give a written consent. Within a week after the end of the treatment all patients are contacted by one of the authors and asked a few standardized questions concerning their compliance with the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Compliance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any patient given antibiotics for any cause

Exclusion Criteria

* Use of mixture instead of tablets
* Tablets administrated by public health care services
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Norwegian Medical Association

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Torunn Bjerve Eide

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mette Brekke, Ph D

Role: STUDY_DIRECTOR

University of Oslo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hisøy legekontor

Arendal, Aust-Agder, Norway

Site Status

Froland legekontor

Frøland, Aust-Agder, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VH-TBE-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.